Literature DB >> 15277917

Effects of anesthetic agents on focal adhesion kinase (pp125FAK) tyrosine phosphorylation in rat hippocampal slices.

Souhayl Dahmani1, Antoine Tesnière, Danielle Rouelle, Madeleine Toutant, Jean-Marie Desmonts, Jean Mantz.   

Abstract

BACKGROUND: Tyrosine protein kinase proteins exert a prominent control on signaling pathways and may couple rapid events, such as action potential and neurotransmitter release, to long-lasting changes in synaptic strength and survival. Whether anesthetics modulate tyrosine kinase activity remains unknown. The aim of the current study was therefore to examine the effects of intravenous and volatile anesthetics on the phosphorylation of focal adhesion kinase (ppFAK), a functionally important nonreceptor tyrosine kinase, in the rat hippocampus.
METHODS: Phosphorylation of ppFAK was examined in hippocampal slices by immunoblotting with both antiphosphotyrosine and specific anti-ppFAK antibodies. Experiments were performed in the absence (control) or presence of various concentrations of pharmacologic or anesthetic agents or both.
RESULTS: Clinically relevant concentrations of thiopental, propofol, etomidate, isoflurane, sevoflurane, and desflurane induced a concentration-related increase in tyrosine phosphorylation. In contrast, ketamine (up to 100 microm) and the nonimmobilizer F6 (1,2-dichlorohexafluorocyclobutane, 25 microm) did not significantly affect ppFAK phosphorylation. The anesthetic-induced increase in ppFAK phosphorylation was blocked by GF 109203X, RO 318220, and chelerythrin (100 microm), three structurally distinct inhibitors of protein kinase C and U 73122 (50 microm), an inhibitor of phospholipase C. The propofol- and isoflurane-induced increase in ppFAK phosphorylation was reversible and showed nonadditivity of effects with phorbol 12-myristate 13-acetate (an activator of protein kinase C, 0.1 microm). In contrast, ketamine (up to 100 microm), MK801 (10 microm, an N-methyl-d-aspartate receptor antagonist), bicuculline (10 microm, a gamma-aminobutyric acid type A receptor antagonist), and dantrolene (30 microm, an inhibitor of the ryanodine receptor) were ineffective in blocking anesthetic-induced activation of tyrosine phosphorylation.
CONCLUSION: Except for ketamine, anesthetic agents markedly increase tyrosine phosphorylation of ppFAK in the rat hippocampus, most likely via the phospholipase C-protein kinase C pathway, whereas the nonimmobilizer F6 does not. These results suggest that ppFAK represents a target for anesthetic action in the brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277917     DOI: 10.1097/00000542-200408000-00015

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  4 in total

1.  Effects of sevoflurane pretreatment on renal Src and FAK expression in diabetic rats after renal ischemia/reperfusion injury.

Authors:  Shao-Peng Zhou; Wei-Tao Liao; Lu-Kun Yang; Liao Sun
Journal:  Mol Cell Biochem       Date:  2013-09-04       Impact factor: 3.396

2.  Biliverdin reductase bridges focal adhesion kinase to Src to modulate synaptic signaling.

Authors:  Chirag Vasavda; Evan R Semenza; Jason Liew; Ruchita Kothari; Ryan S Dhindsa; Shruthi Shanmukha; Anthony Lin; Robert Tokhunts; Cristina Ricco; Adele M Snowman; Lauren Albacarys; Francesco Pastore; Cristian Ripoli; Claudio Grassi; Eugenio Barone; Michael D Kornberg; Xinzhong Dong; Bindu D Paul; Solomon H Snyder
Journal:  Sci Signal       Date:  2022-05-10       Impact factor: 9.517

3.  Propofol induces MAPK/ERK cascade dependant expression of cFos and Egr-1 in rat hippocampal slices.

Authors:  Srivatsan Kidambi; Joel Yarmush; Yevgeny Berdichevsky; Sangeetha Kamath; Wayne Fong; Joseph Schianodicola
Journal:  BMC Res Notes       Date:  2010-07-17

4.  Propofol induces ERK-dependant expression of c-Fos and Egr-1 in neuronal cells.

Authors:  Srivatsan Kidambi; Joel Yarmush; Wayne Fong; Sangeetha Kamath; Joseph Schianodicola; Yaakov Nahmias
Journal:  Neuroreport       Date:  2009-05-06       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.